1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis

A compound of Formula (IIIb):

• or salts thereof, wherein:
• G is:
• (i) phenyl substituted with 1 to 3 substituents independently selected from —OCH3, —S(O)2CH3, —S(O)2N(CH3)2, —S(O)2(cyclopropyl), and —S(O)(NH)N(CH3)2;
• (iv) a 9-membered heterocyclic ring selected from:
• or
• (v) 10-membered heterocyclic ring selected from:
• A is piperidinyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl, or azabicyclo[3.2.1]octanyl, each substituted with -L-R4 and zero to 2 R4b;
• L is a bond, —CRxRx—, or —C(O)(CRxRx)0-2—;
• R1 is hydrogen, C1-3 alkyl, C1-2 fluoroalkyl, or C3-4 cycloalkyl;
• each R2 is independently halo, —CN, —OH, —NO2, C1-4 alkyl, C1-2 fluoroalkyl, C1-2 cyanoalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, —O(CH2)1-2OH, —(CH2)0-4O(C1-4 alkyl), C1-3 fluoroalkoxy, —(CH2)1-4O(C1-3 alkyl), —O(CH2)1-2OC(O)(C1-3 alkyl), —O(CH2)1-2NRxRx, —C(O)O(C1-3 alkyl), —(CH2)0-2C(O)NRyRy, —C(O)NRx(C1-5 hydroxyalkyl), —C(O)NRx(C2-6 alkoxyalkyl), —C(O)NRx(C3-6 cycloalkyl), —NRyRy, —NRy(C1-3 fluoroalkyl), —NRy(C1-4 hydroxyalkyl), —NRxCH2(phenyl), —NRxS(O)2(C3-6 cycloalkyl), —NRxC(O)(C1-3 alkyl), —NRxCH2(C3-6 cycloalkyl), —S(O)2(C1-3 alkyl), —S(O)2N(C1-3 alkyl)2, —S(O)(NH)N(C1-3 alkyl)2, —(CH2)0-2(C3-6 cycloalkyl), —(CH2)0-2(phenyl), morpholinyl, dioxothiomorpholinyl, dimethyl pyrazolyl, methylpiperidinyl, methylpiperazinyl, amino-oxadiazolyl, imidazolyl, triazolyl, or —C(O)(thiazolyl);
• R2a is C1-6 alkyl, C1-3 fluoroalkyl, C1-6 hydroxyalkyl, C1-3 aminoalkyl, —(CH2)0-4O(C1-3 alkyl), C3-6 cycloalkyl, —(CH2)1-3C(O)NRxRx, —CH2(C3-6 cycloalkyl), —CH2(phenyl), tetrahydrofuranyl, tetrahydropyranyl, or phenyl;
• each R2b is independently H, halo, —CN, —NRxRx, C1-6 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C1-3 fluoroalkoxy, —(CH2)0-2O(C1-3 alkyl), —(CH2)0-3C(O)NRxRx, —(CH2)1-3(C3-6 cycloalkyl), —C(O)O(C1-3 alkyl), —C(O)NRx(C1-3 alkyl), —CRx═CRxRx, or —CRx═CH(C3-6 cycloalkyl);
• R2c is R2a or R2b;
• R2d is R2a or R2b;
• provided that one of R2c and R2d is R2a, and the other of R2c and R2d is R2b;
• R3 is hydrogen, F, C1-3 alkyl, or C3-4 cycloalkyl;
• R4 is:
• (i) —N(CH3)2;
• (ii) morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, pyridinyl, dioxothiomorpholinyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl, diazabicyclo[2.2.2]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with zero to 4 R4a;
• or
• each R4a is independently —OH, C1-6 alkyl, C1-3 fluoroalkyl, C3-6 cycloalkyl, —CH2(C3-6 cycloalkyl), —C(O)(C1-4 alkyl), —C(O)(C3-6 cycloalkyl), —C(O)(phenyl), —C(O)CH2(C3-6 cycloalkyl), —C(O)CH2(phenyl), or —C(O)O(C1-4 alkyl);
• each R4b is independently F, Cl, or —CH3;
• each R4c is independently —OH, C1-6 alkyl, C1-3 fluoroalkyl, —CH2(C3-6 cycloalkyl), —C(O)(C1-4 alkyl), —C(O)(phenyl), —C(O)CH2(phenyl), —C(O)OCH2CH3, or C3-6 cycloalkyl;
• each R5 is independently hydrogen, F, Cl, C1-3 alkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, cyclopropyl, or morpholinyl;
• each Rx is independently H or —CH3;
• each Ry is independently H or C1-6 alkyl;
• m is zero, 1, or 2;
• n is zero, 1, or 2;
• and
• p is zero, 1, 2, 3, or 4.